# EDGAR Filing Document

**Accession Number:** 0001885827
**File Stem:** 0000000000-23-003057
**Filing Date:** 2023-3
**Character Count:** 3396
**Document Hash:** 0204142533496a846ab9a472c07d6de7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003057.hdr.sgml**: 20230427

**ACCESSION NUMBER**: 0000000000-23-003057

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230328

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** 30 BROADWICK STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1F 8LX

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950123-23-002979

## Text-Extract

```

United States securities and exchange commission logo

                          March 28, 2023

       James Foster
       Chief Executive Officer
       Virax Biolabs Group Ltd
       20 North Audley Street
       London, W1K 6LX
       United Kingdom

                                                        Re: Virax Biolabs Group
Ltd
                                                            Registration
Statement on Form F-1
                                                            Filed March 22,
2023
                                                            File No. 333-270734

       Dear James Foster:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Lauren
Hamill at 303-844-1008 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Lawrence Venick

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 28, 2023

James Foster
Chief Executive Officer
Virax Biolabs Group Ltd
20 North Audley Street
London, W1K 6LX
United Kingdom

**Re: Virax Biolabs Group Ltd**
**Registration Statement on Form F-1**
**Filed March 22, 2023**
**File No. 333-270734**

Dear James Foster:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Lawrence Venick